Ibrutinib, also known as PCI-32765, is a potent and orally active BTK inhibitor. Ibrutinib binds to and inhibits BTK activity, preventing B-cell activation and B-cell-mediated signaling and inhibiting the growth of malignant B cells that overexpress BTK. Ibrutinib was approved by the US FDA on November 13, 2013 for the treatment of mantle cell lymphoma.
Li, Xixiang; Wang, Aoli; Yu, Kailin; Qi, Ziping; Chen, Cheng; Wang, Wenchao; Hu, Chen; Wu, Hong; Wu, Jiaxin; Zhao, Zheng; Liu, Juan; Zou, Fengming; Wang, Li; Wang, Beilei; Wang, Wei; Zhang, Shanchun; Liu, Jing; Liu, Qingsong. Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia. Journal of Medicinal Chemistry. Volume 58. Issue 24. Pages 9625-9638. Journal; Online Computer File. (2015).
Zhang, Qian; Tang, Meng. Regioselective Synthesis of Highly Functionalized Pyrazoles from N-Tosylhydrazones. Organic Letters. Volume 21. Issue 6. Pages 1917-1920. Journal; Online Computer File. (2019).
Jiang, Xinyi; Xu, Jun; Liu, Ruzhang. Preparation method of ibrutinib as antitumor drug. Assignee Nantong Aba Chemical Co., Ltd., Peop. Rep. China. CN 109180683. (2019).
Maier, Thomas; Karapetyan, Inna; Arakelyan, Alvard; Margaryan, Tamara; Sargsyan, Vardan; Stepanyan, Heghine; Abovyan, Hermine; Gerber Aeschbacher, Roman; Haferkamp, Sven. Synthesis of stable amorphous ibrutinib. Assignee AZAD Pharmaceutical Ingredients AG, Switz. GB 2558514. (2018).
Fang, Tonghua; Chen, Yuling; Jiang, Min; Zhang, Wei; Sun, Ke; Chen, Xin. Process for the preparation of ibrutinib. Assignee Heilongjiang ZBD Pharmaceutical Co., Ltd., Peop. Rep. China; Harbin Zhenbao Pharmaceutical Co., Ltd. CN 107674079. (2018).
Kandagatla, Bhaskar; Sen, Saikat; Oruganti, Srinivas; Dhanukar, Vilas. Process for the preparation of Ibrutinib and its intermediates. Assignee Dr. Reddy's Laboratories Limited, India. IN 2014CH05522. (2016).
Li, Mengyang. Preparation of ibrutinib Assignee Zhengzhou University, Peop. Rep. China. CN 107353291. (2017).
Rajan, Srinivasan Thirumalai; Eswaraiah, Sajja; Madhusudhan, Gutta; Sarma, Peri Seetha Rama. Process for the preparation of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and polymorphs thereof. Assignee MSN Laboratories Private Limited, India. IN 2015CH02055. (2016).
Jayachandra, Sureshbabu; Sebastaian, Sonny; Rao, Jagadeeshwar; Naidu, Himaprasad; Mallareddy, Adla; Mannava, Srinivasa Rao; Sabbella, Suresh Reddy. Process for the preparation of ibrutinib. Assignee Mylan Laboratories Ltd., India. IN 2015CH00777. (2016).
Hsiao, Tsung-Yu; Ho, Mengfen; Tseng, Hsinchang; Tsao, Wenshing; Huang, Yuanchang; Lo, Wei-Shuo. Process for preparing ibrutinib and its intermediates. Assignee ScinoPharm Taiwan, Ltd., Taiwan; ScinoPharm Singapore Pte, Ltd. WO 2017074265. (2017).
